Cited 25 time in
Comparison of Treatment Outcomes for T3 Glottic Squamous Cell Carcinoma: A Meta-Analysis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, Bo Hae | - |
| dc.contributor.author | Park, Sung Joon | - |
| dc.contributor.author | Jeong, Woo-Jin | - |
| dc.contributor.author | Ahn, Soon-Hyun | - |
| dc.date.accessioned | 2023-04-28T09:41:40Z | - |
| dc.date.available | 2023-04-28T09:41:40Z | - |
| dc.date.issued | 2018-03 | - |
| dc.identifier.issn | 1976-8710 | - |
| dc.identifier.issn | 2005-0720 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/9725 | - |
| dc.description.abstract | Objectives. This study compared the survival outcomes, local control rate, and laryngeal preservation rate of various treatment strategies in the treatment of T3 squamous cell carcinoma of the glottis using proportional meta-analyses. Methods. Twenty-five retrospective case-series studies were included in these analyses. Treatment strategies were classified as total laryngectomy (TL), open partial laryngectomy (PL), transoral laser microsurgery (TLM), chemo-radiation therapy (CRT), and radiation therapy (RT) alone. Results. The overall survival rate and disease-specific survival rate among laryngeal preservation treatments did not differ from the overall survival rate of TL. However, the local control rate was lower with RT than TL and PL, and laryngeal preservation rates of TLM and CRT were higher than RT alone. Conclusion. Consideration of preservation of laryngeal function is necessary when treating T3 glottic squamous cell carcinoma. PL,TLM, and, CRT are considered more appropriate initial laryngeal preservation strategies if available. | - |
| dc.format.extent | 8 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | KOREAN SOC OTORHINOLARYNGOL | - |
| dc.title | Comparison of Treatment Outcomes for T3 Glottic Squamous Cell Carcinoma: A Meta-Analysis | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.21053/ceo.2017.00717 | - |
| dc.identifier.scopusid | 2-s2.0-85042453527 | - |
| dc.identifier.wosid | 000427449600001 | - |
| dc.identifier.bibliographicCitation | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY, v.11, no.1, pp 1 - 8 | - |
| dc.citation.title | CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY | - |
| dc.citation.volume | 11 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 8 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART002333375 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Otorhinolaryngology | - |
| dc.relation.journalWebOfScienceCategory | Otorhinolaryngology | - |
| dc.subject.keywordPlus | TRANSORAL LASER MICROSURGERY | - |
| dc.subject.keywordPlus | LARYNGEAL PRESERVATION | - |
| dc.subject.keywordPlus | SUPRACRICOID LARYNGECTOMY | - |
| dc.subject.keywordPlus | CHEMORADIATION THERAPY | - |
| dc.subject.keywordPlus | UNITED-STATES | - |
| dc.subject.keywordPlus | VOCAL CORD | - |
| dc.subject.keywordPlus | RADIOTHERAPY | - |
| dc.subject.keywordPlus | CANCER | - |
| dc.subject.keywordPlus | SURGERY | - |
| dc.subject.keywordPlus | MANAGEMENT | - |
| dc.subject.keywordAuthor | Squamous Cell Carcinoma | - |
| dc.subject.keywordAuthor | Glottis | - |
| dc.subject.keywordAuthor | Survival | - |
| dc.subject.keywordAuthor | Organ Preservation | - |
| dc.subject.keywordAuthor | Meta-Analysis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
